Drug | Disease | DNA mutation | Action |
---|---|---|---|
Imatinib, Dasatinib, Nilotinib, Bosutinib | Chronic myelogenous leukemia | BCR-ABL1 fusion | Indication for therapy |
Ponatinib | Chronic myelogenous leukemia | BCR-ABL1 fusion | Only indicated for T315I mutations |
T315I resistance mutation | |||
Erlotinib, Afatinib | Lung adenocarcinoma | EGFR | Indication for therapy |
Exon 19 deletions | |||
L858R | |||
Vemurafenib, Dabrafenib | Melanoma | BRAF V600E | Indication for therapy |
Tramatenib | Melanoma | BRAF V600E/K | Indication for therapy |
Crizotinib | Lung cancer | ALK gene fusions | Indication for therapy |
Cetuximab | Colon cancer | KRAS codon 12, 13 | Contraindication to therapy |
Olaparib | Ovarian cancer | BRCA1 and BRCA2 mutations | Indication for therapy |